Food and Drug Administration (FDA) for once-weekly CagriSema (cagrilintide 2.4 mg and semaglutide 2.4 mg) injection, to be used with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in adults with obesity or overweight in the presence of at least one weight-related comorbid condition
Growing Research Community Recognition The company continues building recognition among online research communities for professionalism and product consistency
Additionally, we are developing a more sophisticated innervated salivary gland tissue (iSGm) chip model to more faithfully recapitulate the native gland which is highly innervated
Infused with ginseng extract and skin-conditioning amino acids, it provides a gentle, hydrating wash that minimizes fine lines, clears blemishes, and promotes a brighter, smoother, and more youthful complexion
Sun N, Liang Y, Chen Y, Wang L, Li D, Liang Z, et al